Background
This study was conducted to evaluate the efficacy of dietary n-6 and n-3 polyunsaturated fatty acids (PUFAs) in dry eye in
a rat model.
Methods
Female Lewis rats were fed with diets containing (1) γ-linolenic acid (GLA), (2) eicosapentaenoic acid (EPA) + docosahexaenoic
acid (DHA), or (3) GLA + EPA + DHA, for 2 months before the induction of dry eye using a continuous delivery of scopolamine
and during scopolamine treatment. Two, 10 and 28 days after dry-eye induction, clinical signs of corneal dryness were evaluated
in vivo using fluorescein staining. MHC II expression and mucin rMuc5AC production in the conjunctival epithelium were evaluated
by immunostaining. Lipids and prostaglandins (PGs) E1 and E2 were analysed from the exorbital lacrimal gland (LG).
Results
Dietary PUFAs minimised the occurrence of corneal keratitis 28 days after induction of dry eye. The decrease in mucin production
observed on the conjunctival epithelium was partially prevented by EPA + DHA supplementation after 2 days of scopolamine treatment,
as well as by GLA and GLA + EPA + DHA diets after 10 days of treatment. The overexpression of MHC II in the conjunctival epithelium
caused by dry eye induction was significantly reduced only with the GLA + EPA + DHA diet after 28 days of treatment. Dietary
PUFAs were incorporated into phospholipids of the exorbital LG. Induction of dry eye was associated with a significant increase
in PGE1 and PGE2 levels in the exorbital LG, which was inhibited by dietary EPA + DHA at 10 days (for PGE2) and 28 days (for PGE1).
Conclusions
Dietary GLA, EPA and DHA significantly interfered with lipid homeostasis in the exorbital LG and partially prevented the course
of dry eye. In particular, our results demonstrate the efficacy of the combination of n-6 and n-3 PUFAs.
Keywords Dry eye - Inflammation - Polyunsaturated fatty acids - Prostaglandins - Ocular surface - Lacrimal gland
Support: Regional Council of Burgundy (Dijon, France) for S. Viau (PhD fellowship) and C. Joffre (Grant no 29000026) The Nutrition,
Chemical Food Safety and Consumer Behaviour Division from INRA (Dijon, France) for S. Viau (BTH01698) Horus Pharma (Saint
Laurent du Var, France) for C. Joffre (research contract no 29000144)